Biosimilar Patents Vs. Biologic Drugs: Challenges and Opportunities

Abstract

The growing expiration of patents on biologic drugs has catalyzed the entry of biosimilars, offering a significant opportunity to lower healthcare costs and improve patient access to critical therapies, especially in fields like oncology, rheumatology, and endocrinology. However, the transition is fraught with challenges that span legal, regulatory, technical, and market domains. This review explores the complex intersection between biosimilar patents and biologic drug development, focusing on how intellectual property frameworks and global regulatory environments shape market dynamics. Key barriers include patent thickets, litigation strategies, regulatory discrepancies, and skepticism from clinicians and patients about biosimilar efficacy and safety. While biosimilars hold the promise of saving billions in healthcare expenditure, their success depends on international harmonization of regulations, education of healthcare professionals, and policy reform to discourage evergreening. The paper concludes that a balanced ecosystem—where innovation is protected but not monopolized—is essential to unlock the full potential of biosimilars in promoting equitable and sustainable healthcare globally.